Drug development in higher-risk myelodysplastic syndromes

被引：0
|
作者：
Sangeetha Venugopal [1 ]
Mikkael A. Sekeres [1 ]
机构：
[1] University of Miami,Division of Hematology, Sylvester Comprehensive Cancer Center
来源：
Blood Cancer Journal | / 14卷 / 1期
关键词：
D O I：
10.1038/s41408-024-01171-y
中图分类号：
学科分类号：
摘要：
引用
下载
收藏
相关论文
共 50 条
  • [41] Patient, Caregiver, and Physician Perspectives on Communication in Diagnosing and Treating Higher-Risk Myelodysplastic Syndromes: A Qualitative Study
    Maravic, Melissa Culhane
    Land, Natalie
    Prood, Nadya
    Birch, Kelly
    Cagle, Claire
    May, Suepattra G.
    Sabate, Eduardo J.
    Afulezi, Ngozi
    Jhaveri, Teraneh Z.
    Chen, Mindy
    Hassan, Audrey
    Sadek, Islam
    Hogea, Cosmina
    BLOOD, 2023, 142
  • [42] Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes
    Zeidan, Amer M.
    Platzbecker, Uwe
    Bewersdorf, Jan Philipp
    Stahl, Maximilian
    Ades, Lionel
    Borate, Uma
    Bowen, David
    Buckstein, Rena
    Brunner, Andrew
    Carraway, Hetty E.
    Daver, Naval
    Diez-Campelo, Maria
    de Witte, Theo
    DeZern, Amy E.
    Efficace, Fabio
    Garcia-Manero, Guillermo
    Garcia, Jacqueline S.
    Germing, Ulrich
    Giagounidis, Aristoteles
    Griffiths, Elizabeth A.
    Hasserjian, Robert P.
    Hellstrom-Lindberg, Eva
    Iastrebner, Marcelo
    Komrokji, Rami
    Kulasekararaj, Austin G.
    Malcovati, Luca
    Miyazaki, Yasushi
    Odenike, Olatoyosi
    Santini, Valeria
    Sanz, Guillermo
    Scheinberg, Phillip
    Stauder, Reinhard
    van de Loosdrecht, Arjan A.
    Wei, Andrew H.
    Sekeres, Mikkael A.
    Fenaux, Pierre
    BLOOD, 2023, 141 (17) : 2047 - 2061
  • [43] Treatment Utilization and Characteristics Among Patients with Higher-Risk Myelodysplastic Syndromes According to Hypomethylating Agent Use
    Zeidan, Amer M.
    Divino, Victoria
    DeKoven, Mitch
    Shah, Drishti
    Wang, Elizabeth
    Bey, Dawn
    Salimi, Tehseen
    Epstein, Robert S.
    BLOOD, 2021, 138
  • [44] Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?
    Itzykson, R.
    Thepot, S.
    Beyne-Rauzy, O.
    Ame, S.
    Isnard, F.
    Dreyfus, F.
    Salanoubat, C.
    Taksin, A. L.
    Chelgoum, Y.
    Berthon, C.
    Malfuson, J. V.
    Legros, L.
    Vey, N.
    Turlure, P.
    Gardin, C.
    Boehrer, S.
    Ades, L.
    Fenaux, P.
    LEUKEMIA RESEARCH, 2012, 36 (04) : 397 - 400
  • [45] Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study
    Sallman, David A.
    Al Malki, Monzr M.
    Asch, Adam S.
    Wang, Eunice S.
    Jurcic, Joseph G.
    Bradley, Terrence J.
    Flinn, Ian W.
    Pollyea, Daniel A.
    Kambhampati, Suman
    Tanaka, Tiffany N.
    Zeidner, Joshua F.
    Garcia-Manero, Guillermo
    Jeyakumar, Deepa
    Komrokji, Rami
    Lancet, Jeffrey
    Kantarjian, Hagop M.
    Gu, Lin
    Zhang, Yajia
    Tan, Anderson
    Chao, Mark
    O'Hear, Carol
    Ramsingh, Giridharan
    Lal, Indu
    Vyas, Paresh
    Daver, Naval G.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (15) : 2815 - +
  • [46] Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher-risk myelodysplastic syndromes
    Seymour, John F.
    Bennett, John M.
    List, Alan F.
    Mufti, Ghulam J.
    Gore, Steven D.
    Fenaux, Pierre
    Santini, Valeria
    Hetzer, Joel
    Songer, Stephen
    Skikne, Barry S.
    Beach, Charles L.
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 165 (01) : 49 - 56
  • [47] Higher-risk myelodysplastic syndromes. Does the severity of cytopenias at diagnosis have any prognostic significance?
    Calderon, C.
    Falantes, J. F.
    Marquez, F. J.
    Martino, M. L.
    Gonzalez, J.
    Montero, M. I.
    Parody, R.
    Espigado, I.
    Perez-Simon, J. A.
    LEUKEMIA RESEARCH, 2013, 37 : S83 - S83
  • [48] Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine
    Itzykson, Raphael
    Thepot, Sylvain
    Quesnel, Bruno
    Dreyfus, Francois
    Beyne-Rauzy, Odile
    Turlure, Pascal
    Vey, Norbert
    Recher, Christian
    Dartigeas, Caroline
    Legros, Laurence
    Delaunay, Jacques
    Salanoubat, Celia
    Visanica, Sorin
    Stamatoullas, Aspasia
    Isnard, Francoise
    Marfaing-Koka, Anne
    de Botton, Stephane
    Chelghoum, Youcef
    Taksin, Anne-Laure
    Plantier, Isabelle
    Ame, Shanti
    Boehrer, Simone
    Gardin, Claude
    Beach, C. L.
    Ades, Lionel
    Fenaux, Pierre
    BLOOD, 2011, 117 (02) : 403 - 411
  • [49] HOSPITALIZATION AND EMERGENCY ROOM VISITS AMONG PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES BY HYPOMETHYLATING AGENT USE
    Zeidan, A. M.
    Joshi, N.
    Kale, H.
    Wang, W. -J.
    Corman, S.
    Hill, K.
    Salimi, T.
    Epstein, R.
    LEUKEMIA RESEARCH, 2021, 108 : S26 - S26
  • [50] Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes
    Caocci, G.
    Voso, M. T.
    Angelucci, E.
    Stauder, R.
    Cottone, F.
    Abel, G.
    Nguyen, K.
    Platzbecker, U.
    Beyne-Rauzy, O.
    Gaidano, G.
    Invernizzi, R.
    Molica, S.
    Criscuolo, M.
    Breccia, M.
    Luebbert, M.
    Sanpaolo, G.
    Buccisano, F.
    Ricco, A.
    Palumbo, G. A.
    Niscola, P.
    Zhang, H.
    Fenu, S.
    La Nasa, G.
    Mandelli, F.
    Efficace, F.
    LEUKEMIA RESEARCH, 2015, 39 (08) : 859 - 865
12345